October 2022 – England Securities served as the exclusive placement agent to Ossio Ltd. (“Ossio”), a rapidly growing orthopedic fixation technology company, in its $38.5 million Series C financing. This financing, which was led by MVM Partners (“MVM”), a Boston- and London-based growth equity firm, represents England’s 9th transaction in orthopedics, and 5th transaction specifically in foot & ankle orthopedics.

Ossio, based in Woburn, MA and Caesarea, Israel, produces orthopedic implants made with OSSIOfiber® Intelligent Bone Regeneration Technology, a breakthrough in fixation material that provides the first credible solution to the shortcomings of permanent metal hardware, conventional resorbable, and allograft implants. The technology provides for unparalleled mechanical strength and natural bone healing in a non-permanent implant.

“We are delighted to have secured this level of interest and commitment from such an experienced and distinguished medical technology investment firm,” said OSSIO’s Chief Executive Officer, Brian Verrier. “England’s Healthcare Investment Banking team was instrumental in helping us secure an ideal lead investor with relevant orthopedic experience and a focus on companies of our stage.”

“We believe that OSSIO’s novel bio-integrative technology has the potential to transform the orthopedic fixation market,” said MVM’s founding Partner, Dr. Stephen Reeders. “We are excited to support the company’s mission to improve patient outcomes across a broad range of procedures.” Dr. Reeders and his MVM colleague, Dr. Kevin Cheng, join OSSIO’s board of directors as part of this financing.

Verrier continued, “The additional funding will enable us to accelerate further adoption of OSSIOfiber Intelligent Bone Regeneration Technology by orthopedic and podiatric surgeons in the United States. Specifically, we intend to use these funds to fortify new product development, sales force expansion, patient outreach and medical education.”

Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, the material is biointegrative (replaced by natural bone over time) and provides surgeons with a more biologically friendly way to restore patient stability and mobility while leaving nothing permanent behind. More than 10,000 OSSIOfiber implants have already been used in orthopedic surgeries since their commercial introduction in 2019.